COVID‐19 vaccination hesitancy among people with chronic neurological disorders: A position paper

Health risks associated with SARS‐CoV‐2 infection are undisputed. Moreover, the capability of vaccination to prevent symptomatic, severe, and fatal COVID‐19 is recognized. There is also early evidence that vaccination can reduce the chance for long COVID‐19. Nonetheless, the willingness to get vaccinated and receive booster shots remains subpar among people with neurologic disorders. Vaccine scepticism not only jeopardizes collective efforts to end the COVID‐19 pandemic but puts individual lives at risk, as some chronic neurologic diseases are associated with a higher risk for an unfavorable COVID‐19 course.

[1]  D. Zeng,et al.  Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina , 2022, The New England journal of medicine.

[2]  A. Dror,et al.  Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional study of patients infected between March 2020 and November 2021 , 2022, medRxiv.

[3]  C. Gasperini,et al.  Determinants of COVID-19-related lethality in multiple sclerosis: a meta-regression of observational studies , 2022, Journal of Neurology.

[4]  P. Aridon,et al.  Clinical Onset and Multiple Sclerosis Relapse after SARS-CoV-2 Infection , 2021, Neurology international.

[5]  S. Wessely,et al.  Functional Neurological Disorder after Vaccination: A Balanced Approach Informed by History , 2021, The journal of the Royal College of Physicians of Edinburgh.

[6]  P. D. De Jager,et al.  Vaccination Against SARS-CoV-2 in Neuroinflammatory Disease: Early Safety/Tolerability Data , 2021, Multiple Sclerosis and Related Disorders.

[7]  Wei Peng,et al.  COVID‐19 vaccine take‐up rate and safety in adults with epilepsy: Data from a multicenter study in China , 2021, Epilepsia.

[8]  Weihong Lin,et al.  A Survey of Hesitancy and Response to the COVID-19 Vaccine Among Patients With Epilepsy in Northeast China , 2021, Frontiers in Neurology.

[9]  T. Hariyanto,et al.  Epilepsy and the risk of severe coronavirus disease 2019 outcomes: A systematic review, meta-analysis, and meta-regression , 2021, Epilepsy & Behavior.

[10]  I. Ismail,et al.  A systematic review of cases of CNS demyelination following COVID-19 vaccination , 2021, Journal of Neuroimmunology.

[11]  R. Garg,et al.  Spectrum of neurological complications following COVID-19 vaccination , 2021, Neurological Sciences.

[12]  G. Lippi,et al.  Cerebral Venous Thrombosis Developing after COVID-19 Vaccination: VITT, VATT, TTS, and More , 2021, Seminars in Thrombosis and Hemostasis.

[13]  K. Khunti,et al.  Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection , 2021, Nature Medicine.

[14]  V. Tomassini,et al.  Case Report: Multiple Sclerosis Relapses After Vaccination Against SARS-CoV2: A Series of Clinical Cases , 2021, Frontiers in Neurology.

[15]  Hanns-Martin Lorenz,et al.  Neurological autoimmune diseases following vaccinations against SARS‐CoV‐2: a case series , 2021, European journal of neurology.

[16]  Guilherme Diogo Silva,et al.  Guillain‐Barre syndrome following COVID‐19 vaccines: A scoping review , 2021, Acta neurologica Scandinavica.

[17]  E. Schulte,et al.  SARS-CoV-2 vaccination in multiple sclerosis: A clearer picture for the time point during CD20 depleting therapy , 2021, EBioMedicine.

[18]  Ran-Ran Zhang,et al.  Attitudes to Being Vaccinated Against COVID-19: A Survey of People With Epilepsy in China , 2021, Frontiers in Neurology.

[19]  S. R. Vinceti.  COVID-19 Compulsory Vaccination and the European Court of Human Rights , 2021, Acta bio-medica : Atenei Parmensis.

[20]  Evi X. Stavrou,et al.  Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia , 2021, Blood.

[21]  E. Goldman.  How the unvaccinated threaten the vaccinated for COVID-19: A Darwinian perspective , 2021, Proceedings of the National Academy of Sciences.

[22]  H. Kearney,et al.  Vaccine hesitancy among people with multiple sclerosis , 2021, Multiple Sclerosis and Related Disorders.

[23]  F. Scaldaferri,et al.  The educational role of IBD nurses in Italy in vaccinations: do not miss the moment for COVID-19. , 2021, European review for medical and pharmacological sciences.

[24]  David A. Drew,et al.  Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study , 2021, The Lancet Infectious Diseases.

[25]  P. Bhargava,et al.  Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy , 2021, medRxiv.

[26]  V. Tomassini,et al.  mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis , 2021, Journal of Neurology, Neurosurgery, and Psychiatry.

[27]  A. Fasano,et al.  Functional disorders after COVID-19 vaccine fuel vaccination hesitancy , 2021, Journal of Neurology, Neurosurgery, and Psychiatry.

[28]  M. D. Di Battista,et al.  Severe Multiple Sclerosis Relapse After COVID-19 Vaccination: A Case Report , 2021, Frontiers in Neurology.

[29]  A. Bar-Or,et al.  Vaccination and multiple sclerosis in the era of the COVID-19 pandemic , 2021, Journal of Neurology, Neurosurgery, and Psychiatry.

[30]  D. Ehde,et al.  COVID-19 vaccine hesitancy in adults with multiple sclerosis in the United States: A follow up survey during the initial vaccine rollout in 2021 , 2021, Multiple Sclerosis and Related Disorders.

[31]  J. Ferro,et al.  European stroke organization interim expert opinion on cerebral venous thrombosis occurring after SARS-CoV-2 vaccination , 2021, European stroke journal.

[32]  J. Bednařík,et al.  Predictive factors for a severe course of COVID‐19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival , 2021, European journal of neurology.

[33]  T. Okuhara,et al.  Readability assessment of vaccine information: A systematic review for addressing vaccine hesitancy. , 2021, Patient education and counseling.

[34]  K. Freedberg,et al.  Clinical outcomes and cost-effectiveness of COVID-19 vaccination in South Africa , 2021, medRxiv.

[35]  Goran Muric,et al.  COVID-19 Vaccine Hesitancy on Social Media: Building a Public Twitter Data Set of Antivaccine Content, Vaccine Misinformation, and Conspiracies , 2021, JMIR public health and surveillance.

[36]  J. Chodosh,et al.  Barriers to Vaccination Among People with Parkinson's Disease and Implications for COVID-19. , 2021, Journal of Parkinson's disease.

[37]  A. Achiron,et al.  COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021 , 2021, Multiple sclerosis.

[38]  L. Pirofski,et al.  Understanding vaccine hesitancy in COVID-19 , 2021, Med.

[39]  K. Puteikis,et al.  Factors Associated with COVID-19 Vaccine Hesitancy among People with Epilepsy in Lithuania , 2021, International journal of environmental research and public health.

[40]  Manuel Salavisa,et al.  Willingness to be vaccinated against COVID-19: An exploratory online survey in a Portuguese cohort of multiple sclerosis patients , 2021, Multiple Sclerosis and Related Disorders.

[41]  Jinhui Tian,et al.  Nervous system diseases are associated with the severity and mortality of patients with COVID-19: a systematic review and meta-analysis , 2021, Epidemiology and Infection.

[42]  M. Valsecchi,et al.  Strategy to identify priority groups for COVID-19 vaccination: A population based cohort study , 2021, Vaccine.

[43]  P. Rommer,et al.  Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies , 2021, Vaccines.

[44]  A. Pisani,et al.  A plea for equitable global access to COVID‐19 diagnostics, vaccination and therapy: The NeuroCOVID‐19 Task Force of the European Academy of Neurology , 2021, European journal of neurology.

[45]  A. Pisani,et al.  Primary prevention of COVID‐19: Advocacy for vaccination from a neurological perspective , 2021, European journal of neurology.

[46]  A. Kurniawan,et al.  Dementia and outcomes from coronavirus disease 2019 (COVID-19) pneumonia: A systematic review and meta-analysis , 2020, Archives of Gerontology and Geriatrics.

[47]  A. Pisani,et al.  EAN consensus statement for management of patients with neurological diseases during the COVID‐19 pandemic , 2020, European journal of neurology.

[48]  E. Moro,et al.  NeuroCOVID: it's time to join forces globally , 2020, The Lancet Neurology.

[49]  M. Bozzali,et al.  Neurological comorbidity and severity of COVID-19 , 2020, Journal of Neurology.

[50]  J. Arenillas,et al.  Neurological Comorbidity Is a Predictor of Death in Covid-19 Disease: A Cohort Study on 576 Patients , 2020, Frontiers in Neurology.

[51]  A. Pisani,et al.  The international European Academy of Neurology survey on neurological symptoms in patients with COVID‐19 infection , 2020, European journal of neurology.

[52]  Linda Y. Fu,et al.  Planning for a COVID-19 Vaccination Program. , 2020, JAMA.

[53]  Anna M. Acosta,et al.  Cost-effectiveness of adult vaccinations: A systematic review. , 2019, Vaccine.

[54]  R. Butler,et al.  Diagnosing the determinants of vaccine hesitancy in specific subgroups: The Guide to Tailoring Immunization Programmes (TIP). , 2015, Vaccine.